Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience.
about
Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trialsDynamic contrast enhanced MR imaging for evaluation of angiogenesis of hepatocellular nodules in liver cirrhosis in N-nitrosodiethylamine induced rat model.Metabolic and vascular features of dynamic contrast-enhanced breast magnetic resonance imaging and (15)O-water positron emission tomography blood flow in breast cancer.Breast MR with special focus on DW-MRI and DCE-MRIDynamic Contrast-Enhanced Magnetic Resonance Imaging with Gd-EOB-DTPA for the Evaluation of Liver Fibrosis Induced by Carbon Tetrachloride in RatsSynergistic Effect of Anti-Angiogenic and Radiation Therapy: Quantitative Evaluation with Dynamic Contrast Enhanced MR Imaging.The role of dynamic contrast-enhanced MRI in cancer diagnosis and treatment.Imaging of tumor angiogenesis: functional or targeted?Diffusion-weighted magnetic resonance imaging for predicting and detecting early response to chemoradiation therapy of squamous cell carcinomas of the head and neck.Dynamic contrast-enhanced MRI-based biomarkers of therapeutic response in triple-negative breast cancerLiver DCE-MRI Registration in Manifold Space Based on Robust Principal Component AnalysisResidual breast cancer diagnosed by MRI in patients receiving neoadjuvant chemotherapy with and without bevacizumab.Biology and management of inflammatory breast cancer.Diagnostic and therapeutic imaging for cancer: therapeutic considerations and future directions.Tumor response assessments with diffusion and perfusion MRI.Angiogenesis and tumor microenvironment: bevacizumab in the breast cancer model.Correlation of perfusion parameters on dynamic contrast-enhanced MRI with prognostic factors and subtypes of breast cancers.Dynamic contrast-enhanced MRI for oncology drug development.Simultaneous measurement of T1 /B1 and pharmacokinetic model parameters using active contrast encoding (ACE)-MRI.Optimization of arterial spin labeling MRI for quantitative tumor perfusion in a mouse xenograft model.Dynamic contrast-enhanced and diffusion-weighted MRI of estrogen receptor-positive invasive breast cancers: Associations between quantitative MR parameters and Ki-67 proliferation status.Evaluation of therapeutic effect of tumor-targeted therapy.Clinical application of magnetic resonance imaging in management of breast cancer patients receiving neoadjuvant chemotherapy.Linearization improves the repeatability of quantitative dynamic contrast-enhanced MRI.Quantitative magnetic resonance imaging biomarkers in oncological clinical trials: Current techniques and standardization challenges.
P2860
Q26822432-20BF57D3-D712-453A-907C-498559BB7560Q31119452-E6F7E369-7E4C-400F-9CE2-30E17BA2DA76Q33369337-78728A6B-2C0F-4DBF-B5C5-0B64EECC4390Q33965703-102BDE4F-98CE-4EC3-A281-E233F75A34BEQ35664034-227C47F8-DA3D-4E17-91DB-C4A8253EE371Q35919459-7BB97BCC-C829-482B-8E3D-F817C0C51B85Q36457747-2DE62D7F-A465-476F-9A63-E9088D92B039Q36469164-88FE44B3-C8E8-4040-8012-1A519DB8A7BCQ37170947-9F81DD8E-1852-4A1B-881D-7FF35517F04EQ37292720-FE1E3E74-8F7F-4393-B66F-1A89AC15AB7DQ37294075-048E94E8-573C-4295-A2E1-5DD08C6A8D00Q37450606-35E59A37-294C-4D0E-9EAD-EAE141686C90Q37687382-125CA336-ABBD-4092-B506-8C0CE45A9938Q37863631-2BD3A3C2-F178-49AC-8E03-A6405980D8D0Q37995577-6ABE42A7-FE4B-413F-9A14-1D1C044CC4ECQ38245841-214B27C8-94A1-4000-A24B-005706F7B4A2Q38464689-A0179753-2298-4B41-A79F-F30D44D6C215Q38725827-10538B54-F66E-4AA6-AB36-4E1C1555CDCFQ38764089-D637E7BE-AF54-40B5-9D59-641B36624DC3Q38860709-949BCA93-1B04-4672-A152-6AC4CFDC3EA3Q39676450-70507F44-67DE-4F20-B1F7-ADD6F184797BQ41962463-E2C80B1C-7F6B-4E33-A2F1-D15F221DD392Q44491240-B2151DC0-42D7-40F8-9295-D4F60C263F5DQ47332679-5066DF0D-6993-459A-82DB-AA1480CB5DD0Q52904949-7F0970A8-5A67-4EB3-AB69-FCAAC9EE3428
P2860
Inflammatory breast cancer: dynamic contrast-enhanced MR in patients receiving bevacizumab--initial experience.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Inflammatory breast cancer: dy ...... vacizumab--initial experience.
@en
type
label
Inflammatory breast cancer: dy ...... vacizumab--initial experience.
@en
prefLabel
Inflammatory breast cancer: dy ...... vacizumab--initial experience.
@en
P2093
P1433
P1476
Inflammatory breast cancer: dy ...... evacizumab--initial experience
@en
P2093
Arpi Thukral
Betty J Wise
Catherine K Chow
David J Liewehr
David M Thomasson
Peter L Choyke
Reyes Eulate
Sandeep N Gupta
Seth M Steinberg
Suparna B Wedam
P304
P356
10.1148/RADIOL.2443060926
P407
P577
2007-09-01T00:00:00Z